IntelliPharmaCeutics International (IntelliPharmaCeutics International) Total Current Assets : $0.86 Mil (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. IntelliPharmaCeutics International's total current assets for the quarter that ended in Aug. 2023 was $0.86 Mil.

IntelliPharmaCeutics International Total Current Assets Historical Data

The historical data trend for IntelliPharmaCeutics International's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Total Current Assets Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Total Current Assets

Get a 7-Day Free Trial

8.72

1.52

1.48

1.10

0.49

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Total Current Assets	Get a 7-Day Free Trial															0.56	0.49	0.74	0.95	0.86

IntelliPharmaCeutics International Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

IntelliPharmaCeutics International's Total Current Assets for the fiscal year that ended in Nov. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.084	+	0.389	+	0	+	0.02
	=	0.49

IntelliPharmaCeutics International's Total Current Assets for the quarter that ended in Aug. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.4	+	0.268	+	0	+	0.194
	=	0.86

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

IntelliPharmaCeutics International (OTCPK:IPCIF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

IntelliPharmaCeutics International's Liquidation Value for the quarter that ended in Aug. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.4	-	14.442	+	0.75 * 0	+	0.5 * 0
=	-14.04

IntelliPharmaCeutics International Total Current Assets Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.